Knight Therapeutics (OTCMKTS:KHTRF) Stock Price Down 2% – Here’s Why

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares were down 2% during trading on Monday . The company traded as low as $4.56 and last traded at $4.56. Approximately 800 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 2,694 shares. The stock had previously closed at $4.66.

Knight Therapeutics Price Performance

The business has a 50-day moving average price of $4.58 and a 200 day moving average price of $4.37.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.